Formycon AG
0W4N.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$339.67M
Close$
$-16.77
181.6% downside
Current Fair Value
181.6% downsideOvervalued by 181.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $339.67 Million |
|---|---|
| Enterprise Value | $296.40 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.66 |
| Beta | 0.72 |
| Outstanding Shares | 17,672,927 |
Return
| Return on Equity | -50.55% |
|---|---|
| Return on Assets | -27.31% |
| Return on Invested Capital | -23.16% |
Valuation & Multiples
| P/E Ratio | -13.42 |
|---|---|
| PEG | 18.39 |
| Price to Sales | 3.43 |
| Price to Book Ratio | 0.98 |
| Enterprise Value to Revenue | 2.62 |
| Enterprise Value to EBIT | -1.94 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$15.25 M
Average shareholder expectationNext Earnings Call
Expected Date
April 29, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$25.20 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Formycon AG
203 employees
CEO: Stefan Glombitza Formycon AG, established in 1999 and headquartered in Planegg, Germany, focuses on the creation and commercialization of biosimilar pharmaceutical products. The company's diverse pipeline includes several key drug candidates. Prominently...